NASDAQ:AVGR Avinger - AVGR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.82 0.00 (0.00%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.82▼$0.8350-Day Range$0.81▼$1.5352-Week Range$0.80▼$3.92Volume20,893 shsAverage Volume61,171 shsMarket Capitalization$8.25 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Avinger MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside1,000.2% Upside$9.00 Price TargetShort InterestHealthy0.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 3 Articles This WeekInsider TradingSelling Shares$181 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.50 out of 5 stars 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Avinger has a forecasted upside of 1,000.2% from its current price of $0.82.Amount of Analyst CoverageAvinger has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.74% of the float of Avinger has been sold short.Short Interest Ratio / Days to CoverAvinger has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avinger has recently decreased by 15.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvinger does not currently pay a dividend.Dividend GrowthAvinger does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVGR. Previous Next 1.7 News and Social Media Coverage News SentimentAvinger has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Avinger this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Avinger to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avinger insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $181.00 in company stock.Percentage Held by InsidersOnly 0.49% of the stock of Avinger is held by insiders.Percentage Held by InstitutionsOnly 14.14% of the stock of Avinger is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Avinger is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avinger is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvinger has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avinger (NASDAQ:AVGR) StockAvinger, Inc. is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its products include Pantheris, Lightbox, Ocelot, Wildcat, Juicebox, and Kittycat. The company was founded by John B. Simpson and Himanshu N. Patel on March 8, 2007 and is headquartered in Redwood City, CA.Read More Receive AVGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avinger and its competitors with MarketBeat's FREE daily newsletter. Email Address AVGR Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comAvinger (NASDAQ:AVGR) Coverage Initiated at StockNews.comMarch 17, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Avinger (NASDAQ:AVGR)March 25, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 17, 2023 | americanbankingnews.comContrasting Avinger (NASDAQ:AVGR) & Motus GI (NASDAQ:MOTS)March 15, 2023 | finance.yahoo.comAvinger Reports Fourth Quarter 2022 ResultsMarch 15, 2023 | americanbankingnews.comFinancial Survey: Avinger (NASDAQ:AVGR) and NovoCure (NASDAQ:NVCR)March 2, 2023 | finance.yahoo.comAvinger to Announce Fourth Quarter 2022 Results on March 15February 4, 2023 | msn.comDogged determination makes SDSU’s Asia Avinger a ‘pest’ — and one of the bestMarch 25, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!January 11, 2023 | finance.yahoo.comAvinger Announces 510(k) Filing of Pantheris LVNovember 12, 2022 | finance.yahoo.comAvinger Third Quarter 2022 Earnings: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)November 9, 2022 | finance.yahoo.comAvinger Reports Third Quarter 2022 ResultsNovember 4, 2022 | finance.yahoo.comAvinger Announces Issuance of Seven New Patents Expanding Coverage for Its Proprietary Image-Guided Atherectomy DevicesNovember 1, 2022 | finance.yahoo.comAvinger to Announce Third Quarter 2022 Results on November 9October 19, 2022 | benzinga.comAvinger to Present at LD Micro Investor Conference - Avinger (NASDAQ:AVGR) - BenzingaOctober 19, 2022 | finance.yahoo.comAvinger to Present at LD Micro Investor ConferenceSeptember 26, 2022 | globenewswire.comMedical Coatings Market to Reach USD 8.20 Billion by 2029 | Exhibit CAGR of 9.8% (2022-2029) - GlobeNewswireSeptember 15, 2022 | finance.yahoo.comAvinger, Inc. (AVGR)September 14, 2022 | msn.comText about hitchhiker likely sent by alleged killer of Avinger man, sheriff saysSeptember 12, 2022 | businesswire.comUnited States Peripheral Artery Disease Interventions Market Landscape Report 2022: Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook - ResearchAndMarkets.com - Business WireSeptember 8, 2022 | benzinga.comAvinger Inc. (AVGR) – Avinger's Return On Capital Employed Insights - BenzingaSeptember 7, 2022 | benzinga.com(AFIB), Avinger Inc. (AVGR) – BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Eli - BenzingaSeptember 7, 2022 | globenewswire.comBrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council - GlobeNewswireSeptember 2, 2022 | nytimes.comStephen Curry’s Graduation From Davidson Was a Long Time Coming - The New York TimesSeptember 1, 2022 | benzinga.comAvinger Inc. (AVGR) – Avinger Announces Interim Data From IMAGE-BTK Clinical Trial Presented At AMP 2022 - BenzingaSeptember 1, 2022 | benzinga.comAvinger Inc. (AVGR) – Interim Data from IMAGE-BTK Clinical Trial Presented at AMP 2022 - BenzingaAugust 20, 2022 | rttnews.comPre-market Movers: BRSH, CDAK, BWV, WOLF, AVGR… - RTTNewsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avinger and its competitors with MarketBeat's FREE daily newsletter. Email Address AVGR Company Calendar Last Earnings11/11/2021Today3/25/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVGR CUSIPN/A CIK1506928 Webwww.avinger.com Phone(650) 241-7900Fax800-229-2696Employees68Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$9.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+1,000.2%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($4.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,620,000.00 Net Margins-213.02% Pretax Margin-213.02% Return on Equity-286.05% Return on Assets-63.55% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio0.89 Sales & Book Value Annual Sales$8.27 million Price / Sales1.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book1.46Miscellaneous Outstanding Shares10,080,000Free Float10,034,000Market Cap$8.25 million OptionableNot Optionable Beta1.52 Key ExecutivesJeffrey M. SoinskiPresident, Chief Executive Officer & DirectorNabeel SubainatiChief Financial & Accounting OfficerHimanshu N. PatelChief Technology OfficerJaafer GolzarChief Medical OfficerPhilip R. PreussVice President-Marketing & Business OperationsKey CompetitorsMinerva SurgicalNASDAQ:UTRSGlucoTrackNASDAQ:GCTKIntegrity ApplicationsNASDAQ:IGAPDynatronicsNASDAQ:DYNTVivos TherapeuticsNASDAQ:VVOSView All CompetitorsInsiders & InstitutionsNabeel Paul SubainatiSold 223 sharesTotal: $180.63 ($0.81/share)Armistice Capital LLCBought 52,000 shares on 2/15/2023Ownership: 9.684%View All Insider TransactionsView All Institutional Transactions AVGR Stock - Frequently Asked Questions What is Avinger's stock price forecast for 2023? 0 brokerages have issued twelve-month price objectives for Avinger's shares. Their AVGR share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 1,000.2% from the stock's current price. View analysts price targets for AVGR or view top-rated stocks among Wall Street analysts. How have AVGR shares performed in 2023? Avinger's stock was trading at $1.0850 at the beginning of the year. Since then, AVGR shares have decreased by 24.6% and is now trading at $0.8180. View the best growth stocks for 2023 here. When is Avinger's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our AVGR earnings forecast. How were Avinger's earnings last quarter? Avinger, Inc. (NASDAQ:AVGR) posted its earnings results on Thursday, November, 11th. The medical device company reported ($1.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.40) by $0.20. The medical device company earned $2.37 million during the quarter, compared to the consensus estimate of $2.52 million. Avinger had a negative net margin of 213.02% and a negative trailing twelve-month return on equity of 286.05%. During the same period in the prior year, the firm earned ($1.60) earnings per share. When did Avinger's stock split? Avinger shares reverse split on the morning of Tuesday, March 15th 2022. The 1-20 reverse split was announced on Tuesday, March 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Avinger own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Organigram (OGI), Onconova Therapeutics (ONTX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM). When did Avinger IPO? (AVGR) raised $60 million in an initial public offering on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company acted as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers. What is Avinger's stock symbol? Avinger trades on the NASDAQ under the ticker symbol "AVGR." Who are Avinger's major shareholders? Avinger's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.68%). Insiders that own company stock include Himanshu Patel, James Cullen, Jeffrey M Soinski, Mark Weinswig and Nabeel Paul Subainati. View institutional ownership trends. How do I buy shares of Avinger? Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avinger's stock price today? One share of AVGR stock can currently be purchased for approximately $0.82. How much money does Avinger make? Avinger (NASDAQ:AVGR) has a market capitalization of $8.25 million and generates $8.27 million in revenue each year. The medical device company earns $-17,620,000.00 in net income (profit) each year or ($4.74) on an earnings per share basis. How can I contact Avinger? Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.avinger.com. The medical device company can be reached via phone at (650) 241-7900, via email at info@dawson3d.com, or via fax at 800-229-2696. This page (NASDAQ:AVGR) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.